Methods for gas-phase deoxygenation of a bio-oil are provided. In embodiments, such a method comprises exposing a bio-oil vapor comprising hydrocarbon compounds having oxygenated aromatic groups, to hydrogen gas in the presence of catalyst under conditions to induce deoxygenation of the oxygenated aromatic groups to provide a deoxygenated aromatic species, wherein the catalyst is a transition metal-incorporated mesoporous silicate having platinum deposited thereon and the transition metal is selected from Nb, W, Zr, and combinations thereof. The transition metal-incorporated mesoporous silicate catalysts are also provided.

Methods for gas-phase deoxygenation of a bio-oil are provided. In embodiments, such a method comprises exposing a bio-oil vapor comprising hydrocarbon compounds having oxygenated aromatic groups, to hydrogen gas in the presence of catalyst under conditions to induce deoxygenation of the oxygenated aromatic groups to provide a deoxygenated aromatic species, wherein the catalyst is a transition metal-incorporated mesoporous silicate having platinum deposited thereon and the transition metal is selected from Nb, W, Zr, and combinations thereof. The transition metal-incorporated mesoporous silicate catalysts are also provided.

Methods for gas-phase deoxygenation of a bio-oil are provided. In embodiments, such a method comprises exposing a bio-oil vapor comprising hydrocarbon compounds having oxygenated aromatic groups, to hydrogen gas in the presence of catalyst under conditions to induce deoxygenation of the oxygenated aromatic groups to provide a deoxygenated aromatic species, wherein the catalyst is a transition metal-incorporated mesoporous silicate having platinum deposited thereon and the transition metal is selected from Nb, W, Zr, and combinations thereof. The transition metal-incorporated mesoporous silicate catalysts are also provided.

A compound according to structure USYDS1: ##STR00001##
wherein the compound is in purified form.

A compound according to structure USYDS1: ##STR00001##
wherein the compound is in purified form.

The present disclosure relates to cannabigerol sulfonate esters and processes for their use to prepare cannabigerol (CBG) and related compounds, including cannabigerobutol (CBGB), cannabigerovarin (CBGV), and cannabigerophorbol (CBGP). In a preferred embodiment, the cannabigerol sulfonate ester is (E)-4-(3, 7-5 dimethylocta-2,6-dienyl)-3,5-bis(trimethylsilyloxy)phenylromethanesulfonate. In a preferred process, the trifluoromethansulfonate leaving group is replaced by an alkyl group. The disclosure also relates to the use of catalysts and catalytic processes for the preparation of cannabigerol and related compounds from the cannabigerol sulfonate esters.

The present disclosure relates to cannabigerol sulfonate esters and processes for their use to prepare cannabigerol (CBG) and related compounds, including cannabigerobutol (CBGB), cannabigerovarin (CBGV), and cannabigerophorbol (CBGP). In a preferred embodiment, the cannabigerol sulfonate ester is (E)-4-(3, 7-5 dimethylocta-2,6-dienyl)-3,5-bis(trimethylsilyloxy)phenylromethanesulfonate. In a preferred process, the trifluoromethansulfonate leaving group is replaced by an alkyl group. The disclosure also relates to the use of catalysts and catalytic processes for the preparation of cannabigerol and related compounds from the cannabigerol sulfonate esters.

A compound, composition, or method for treating cancer is disclosed. The compound (that can be used in the composition and/or method) can include

##STR00001##

or pharmaceutically acceptable salts or solvates thereof. R.sup.1a-R.sup.1d, R.sup.2-R.sup.3 (and R.sup.4 where applicable), and A---B can be as defined herein.

A compound, composition, or method for treating cancer is disclosed. The compound (that can be used in the composition and/or method) can include

##STR00001##

or pharmaceutically acceptable salts or solvates thereof. R.sup.1a-R.sup.1d, R.sup.2-R.sup.3 (and R.sup.4 where applicable), and A---B can be as defined herein.

The present invention relates to processes for the preparation of empagliflozin. In particular, the present invention relates to the preparation of empagliflozin and intermediates thereof. The present invention also relates to co-crystal of empagliflozin and amino acid and amorphous form of empagliflozin.